0.6364

4.88% 0.0296

Nektar Therapeutics (NKTR)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Nektar Therapeutics stock is traded at $0.6364, with a volume of 1.99M. It is up +4.88% in the last 24 hours and down -30.01% over the past month. Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.

Previous Close:

$0.6068

Open:

$0.6

24h Volume:

1.99M

Relative Volume:

0.87

Market Cap:

$112.39M

Revenue:

$90.12M

Net Income/Loss:

$-276.06M

P/E Ratio:

-0.4359

EPS:

-1.46

Net Cash Flow:

$-193.47M

1W Performance:

+27.51%

1M Performance:

-30.01%

6M Performance:

-56.11%

1Y Performance:

-52.86%

1-Day Range:

$0.60

$0.6569

1-Week Range:

$0.5279

$0.6809

52-Week Range:

$0.432

$1.928

Nektar Therapeutics Stock (NKTR) Company Profile

Name

Nektar Therapeutics

Sector

Healthcare (1151)

Industry

Biotechnology (660)

Phone

(415) 482-5300

Address

455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA

Employee

Twitter

@nektarnews

Next Earnings Date

2025-03-12

Latest SEC Filings

NKTR's Discussions on Twitter

Compare NKTR with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NKTR Nektar Therapeutics	0.6364	112.39M	90.12M	-276.06M	-193.47M	-1.46
VRTX Vertex Pharmaceuticals Inc	489.10	127.47B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	563.16	62.43B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	596.20	37.03B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	234.56	31.06B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	230.98	26.16B	3.81B	-644.79M	-669.77M	-6.24

Nektar Therapeutics Stock (NKTR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-11-25	Upgrade	Jefferies	Hold → Buy
Mar-14-25	Upgrade	Oppenheimer	Perform → Outperform
Jan-08-25	Initiated	B. Riley Securities	Buy
Dec-10-24	Initiated	H.C. Wainwright	Buy
Nov-04-24	Initiated	Piper Sandler	Overweight
Sep-30-24	Resumed	BTIG Research	Buy
Jun-28-24	Initiated	Rodman & Renshaw	Buy
Nov-20-23	Resumed	JP Morgan	Underweight
Nov-09-23	Upgrade	TD Cowen	Market Perform → Outperform
May-10-23	Upgrade	Jefferies	Underperform → Hold
Feb-24-23	Downgrade	Jefferies	Hold → Underperform
Aug-08-22	Downgrade	JP Morgan	Neutral → Underweight
May-31-22	Resumed	Jefferies	Hold
Apr-18-22	Downgrade	Goldman	Neutral → Sell
Mar-15-22	Downgrade	Cowen	Outperform → Market Perform
Mar-15-22	Downgrade	Mizuho	Buy → Neutral
Mar-14-22	Downgrade	BTIG Research	Buy → Neutral
Mar-14-22	Downgrade	BofA Securities	Neutral → Underperform
Mar-14-22	Downgrade	Stifel	Buy → Hold
Mar-14-22	Downgrade	William Blair	Outperform → Mkt Perform
Mar-09-22	Upgrade	Oppenheimer	Perform → Outperform
Nov-08-21	Upgrade	The Benchmark Company	Hold → Buy
Sep-10-21	Initiated	BofA Securities	Neutral
Jun-28-21	Upgrade	Stifel	Hold → Buy
May-18-21	Resumed	Goldman	Neutral
Feb-22-21	Downgrade	The Benchmark Company	Buy → Hold
Jan-06-21	Initiated	Stifel	Hold
Sep-14-20	Initiated	JP Morgan	Neutral
Jun-10-20	Downgrade	CFRA	Hold → Sell
May-12-20	Reiterated	H.C. Wainwright	Neutral
Apr-22-20	Initiated	The Benchmark Company	Buy
Mar-30-20	Upgrade	Goldman	Sell → Neutral
Mar-04-20	Initiated	Barclays	Overweight
Feb-03-20	Upgrade	Mizuho	Neutral → Buy
Oct-24-19	Initiated	Oppenheimer	Perform
Oct-08-19	Downgrade	Goldman	Buy → Sell
Aug-09-19	Downgrade	JP Morgan	Overweight → Neutral
Aug-09-19	Downgrade	Jefferies	Buy → Hold
Aug-09-19	Downgrade	Mizuho	Buy → Neutral
Mar-15-19	Initiated	SVB Leerink	Mkt Perform
Dec-13-18	Initiated	Goldman	Buy
Jun-11-18	Downgrade	H.C. Wainwright	Buy → Neutral
Jun-04-18	Reiterated	H.C. Wainwright	Buy
Apr-20-18	Initiated	Seaport Global Securities	Buy
Apr-13-18	Resumed	Piper Jaffray	Overweight
Apr-06-18	Reiterated	Mizuho	Buy
Apr-02-18	Resumed	H.C. Wainwright	Buy

View All

Nektar Therapeutics Stock (NKTR) Latest News

Apr 16, 2025

Treg Cell-Based Therapies Pipeline: 51+ Innovators Shaping the Future of Immunotherapy | DelveInsight - openPR.com

Apr 16, 2025

Jefferies Upgrades Nektar Therapeutics to Buy, Doubles Price Target to $2.00 - Yahoo Finance

Apr 11, 2025

Nektar Therapeutics Shares Rise After Upgrade From Jefferies - marketscreener.com

Apr 11, 2025

Why Is Nektar (NKTR) Down 38.8% Since Last Earnings Report? - Yahoo Finance

Apr 11, 2025

Nektar Therapeutics stock upgraded at Jefferies (NKTR:NASDAQ) - Seeking Alpha

Apr 11, 2025

Assessing Nektar Therapeutics: Insights From 5 Financial Analysts - Benzinga

Apr 11, 2025

Jefferies Upgrades Nektar Therapeutics to Buy From Hold, Adjusts Price Target to $2 From $1 - MarketScreener

Apr 11, 2025

Jefferies raises Nektar stock to buy, doubles price target By Investing.com - Investing.com India

Apr 11, 2025

Jefferies Upgrades Nektar Therapeutics (NKTR) to Buy - StreetInsider

Apr 11, 2025

Apr 10, 2025

IL-2 ADding contenders in eczema strategy - BioWorld MedTech

Apr 10, 2025

Apr 09, 2025

Nektar Therapeutics stock hits 52-week low at $0.44 By Investing.com - Investing.com Canada

Apr 09, 2025

Nektar Therapeutics stock hits 52-week low at $0.44 - Investing.com

Apr 09, 2025

Apr 04, 2025

Little Excitement Around Nektar Therapeutics' (NASDAQ:NKTR) Revenues As Shares Take 29% Pounding - simplywall.st

Apr 04, 2025

Mar 31, 2025

Q1 Dermatology Drug & Device Report: FDA Approvals & Pipeline Updates - Dermatology Times

Mar 31, 2025

Mar 29, 2025

Nektar Therapeutics announces $75 million equity distribution - Investing.com Australia

Mar 29, 2025

Mar 28, 2025

Nektar Therapeutics announces $75 million equity distribution By Investing.com - Investing.com South Africa

Mar 28, 2025

Nektar TherapeuticsEnters Equity Distribution Agreement Up To $75 MillionSEC Filing - Marketscreener.com

Mar 28, 2025